Devine SM, Bo-Subait S, Kuxhausen M, et al. Clinical Impact of Cryopreservation of Allogeneic Hematopoietic Cell Grafts During the Onset of the COVID-19 Pandemic. Blood Advances. 2023; (doi: 10.1182/bloodadvances.2023009786).
An analysis of graft cryopreservation, as mandated by the National Marrow Donor Program at the onset of the COVID-19 pandemic, supports the recommendation for fresh grafts as pandemic-related logistical challenges settle, while cryopreservation should be considered when fresh grafts are not possible. Cryopreservation did not significantly affect overall survival (OS), severe acute graft-versus host-disease (GVHD), or non-relapse mortality at 12 months following hematopoietic cell transplantation (HCT), the data show. The analysis compared 1,543 cryopreserved allograft recipients who underwent HCT at U.S. centers in the first 6 months of the pandemic with 2,499 patients who received fresh allografts during the same period in 2019. Neither graft recipient cohort differed in terms of OS, non-relapse mortality, GVHD, or GVHD-free, relapse-free survival. A higher relapse risk led to a lower rate of disease-free survival in the cryopreserved group. There was a lower risk of chronic GVHD in the cryopreservation group, but the risk of primary graft failure was higher.
Tags: GVHD, Acute GVHD, cGVHD, chronic GVHD, graft-vs-host disease, chronic graft-versus-host disease, graft-versus-host